CANY
OVID icon

Caxton Associates (New York)’s Ovid Therapeutics OVID Stock Holding History

Caxton Associates (New York)’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,386
Closed -$55K – 696
2022
Q1 		$55K Hold
17,386
– – ﹤0.01% 486
2021
Q4 		$56K Hold
17,386
– – 0.01% 538
2021
Q3 		$58K Hold
17,386
– – 0.01% 432
2021
Q2 		$68K Hold
17,386
– – 0.01% 456
2021
Q1 		$70K Buy
+17,386
New +$57.7K 0.01% 407

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Caxton Associates (New York)'s OVID Position: Q2 2022 in Review

Caxton Associates (New York) sold out of Ovid Therapeutics (OVID) in Q2 2022, closing a stake of 17,386 shares — an estimated $55K sold.

Caxton Associates (New York) first reported a position in OVID in Q1 2021 and held it in 5 quarters. The position peaked at $70K in Q1 2021. 55 funds tracked by Wall St. Rank hold OVID as of Q2 2022.

  • Caxton Associates (New York) reported no remaining Ovid Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 17,386 Ovid Therapeutics shares in Q2 2022, an estimated $55K.
  • Caxton Associates (New York) first reported a position in Ovid Therapeutics in Q1 2021 and held it in 5 quarters.
  • Caxton Associates (New York)'s Ovid Therapeutics position peaked at $70K in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.